BioSpace News Archive

An abstract of this study was presented at the 12th Annual Regional Therapies International Symposium in Snowbird, Utah in February 2017.

Janssen’s Tremfya is now approved in the U.S., Canada and the European Union

The first $150 million is available immediately and an additional tranche of $50 million is available for draw by March 2019.

Appian announced a global partnership to deliver end-to-end, low-code solutions to Life Sciences companies around the world.

This innovative technology, designed to improve processes in fertility laboratories, will be commercially available to IVF clinics in the U.S. in the first half of 2018.

Mr. Kung will help manage the development of PMV Pharma’s mutant p53 restoration drug pipeline, which got a boost this past February when the company completed a $74M series B financing round.

Ocular Therapeutix announced that management will be hosting investor meetings at the Guggenheim Securities 5th Annual Boston Healthcare Conference on Wednesday, December 13, 2017 at The InterContinental Boston Hotel in Boston, Massachusetts.

To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024.

PerkinElmer announced a collaboration with TeakOrigin, a company that integrates technology and data platforms to serve as a detector for food authenticity and quality.

False statements about a botulinum toxin strain and concerns about integrity of data and the impact on patient safety are at the core of a Citizen Petition filed today asking the U.S. Food and Drug Administration (FDA) not to approve the neurotoxin product made by Daewoong Pharmaceuticals Co., Ltd. that is the subject of a Biological Product Application (BLA) submitted by Evolus Inc.